Journal
EXPERIMENTAL AND THERAPEUTIC MEDICINE
Volume 13, Issue 2, Pages 389-394Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/etm.2017.4024
Keywords
interleukin-9; interleukin-9 receptor; asthma; allergic inflammation; treatment
Categories
Funding
- National Natural Science Foundation of China [81400021]
- Jiangsu Natural Science Foundation of China [BK20140125]
Ask authors/readers for more resources
Initially identified as a T cell and mast cell growth factor, interleukin (IL)-9 has long been recognized as an important mediator of asthma. Recently, accumulating results from transgenic mice demonstrated that systemic or lung-specific overexpression of IL-9 caused asthma-associated symptoms. Moreover, anti-mIL-9 antibody (Ab) blocking treatment alleviated disease in animal models of asthma. In light of the large quantity of data from the murine models, MEDI-528, a humanized anti-IL-9 monoclonal Ab has been produced to assess the activity of IL-9 on human asthma. In order to ascertain whether it is a successful translation from bench to bedside, the biological features of IL-9 were evaluated and up-to-date information regarding the role of IL-9 in different experimental murine models and human asthma were summarized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available